Cargando…
Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients
Hearing-preserving partial resection of neurofibromatosis type 2 (NF2) associated vestibular schwannomas (VS) is a preferred treatment strategy, particularly for children and adolescents. However, the residual tumors do grow and lead at some point to continued hearing deterioration. An adjuvant beva...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966588/ https://www.ncbi.nlm.nih.gov/pubmed/31769423 http://dx.doi.org/10.3390/cancers11121862 |
_version_ | 1783488770577793024 |
---|---|
author | Gugel, Isabel Kluwe, Lan Zipfel, Julian Teuber, Christian Tatagiba, Marcos Mautner, Victor-Felix Schuhmann, Martin Ulrich Grimm, Florian |
author_facet | Gugel, Isabel Kluwe, Lan Zipfel, Julian Teuber, Christian Tatagiba, Marcos Mautner, Victor-Felix Schuhmann, Martin Ulrich Grimm, Florian |
author_sort | Gugel, Isabel |
collection | PubMed |
description | Hearing-preserving partial resection of neurofibromatosis type 2 (NF2) associated vestibular schwannomas (VS) is a preferred treatment strategy, particularly for children and adolescents. However, the residual tumors do grow and lead at some point to continued hearing deterioration. An adjuvant bevacizumab treatment may provide an option for slowing down this process. In this retrospective study, we reviewed tumor volume and hearing data of 16 operated VS in nine patients younger than 30 years over a period of 63 to 142 months. All these patients had one or more bevacizumab treatment periods and most of them had a non-treatment period after surgery. Four different patterns of growth were observed for the residual tumors: (1) growth in the non-treatment periods, which slowed down in the treatment periods; (2) growth slowed down in one but not in another on-period; (3) unaffected growth; (4) no or minimal growth regardless of the treatment. Neither radiological regression of tumor volume nor hearing improvement were observed in the treatment periods. Accelerated hearing deterioration was observed in several non-treatment periods, but also in some treatment periods. No straightforward correlation can be drawn between tumor growth and hearing scores. Tumor growth and worsening of hearing between two measurement points were slightly less in the treatment periods; however, the differences were not significant, because variations were large. In conclusion, our comprehensive follow-up on 16 VS in nine NF2 patients did show heterogenous effects of bevacizumab on small residual vestibular schwannomas after surgery both regarding tumor size and hearing preservation. Thus, smaller and slower growing tumor residuals seem to behave differently to bevacizumab than reported for not-operated faster growing VS. |
format | Online Article Text |
id | pubmed-6966588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69665882020-02-04 Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients Gugel, Isabel Kluwe, Lan Zipfel, Julian Teuber, Christian Tatagiba, Marcos Mautner, Victor-Felix Schuhmann, Martin Ulrich Grimm, Florian Cancers (Basel) Article Hearing-preserving partial resection of neurofibromatosis type 2 (NF2) associated vestibular schwannomas (VS) is a preferred treatment strategy, particularly for children and adolescents. However, the residual tumors do grow and lead at some point to continued hearing deterioration. An adjuvant bevacizumab treatment may provide an option for slowing down this process. In this retrospective study, we reviewed tumor volume and hearing data of 16 operated VS in nine patients younger than 30 years over a period of 63 to 142 months. All these patients had one or more bevacizumab treatment periods and most of them had a non-treatment period after surgery. Four different patterns of growth were observed for the residual tumors: (1) growth in the non-treatment periods, which slowed down in the treatment periods; (2) growth slowed down in one but not in another on-period; (3) unaffected growth; (4) no or minimal growth regardless of the treatment. Neither radiological regression of tumor volume nor hearing improvement were observed in the treatment periods. Accelerated hearing deterioration was observed in several non-treatment periods, but also in some treatment periods. No straightforward correlation can be drawn between tumor growth and hearing scores. Tumor growth and worsening of hearing between two measurement points were slightly less in the treatment periods; however, the differences were not significant, because variations were large. In conclusion, our comprehensive follow-up on 16 VS in nine NF2 patients did show heterogenous effects of bevacizumab on small residual vestibular schwannomas after surgery both regarding tumor size and hearing preservation. Thus, smaller and slower growing tumor residuals seem to behave differently to bevacizumab than reported for not-operated faster growing VS. MDPI 2019-11-25 /pmc/articles/PMC6966588/ /pubmed/31769423 http://dx.doi.org/10.3390/cancers11121862 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gugel, Isabel Kluwe, Lan Zipfel, Julian Teuber, Christian Tatagiba, Marcos Mautner, Victor-Felix Schuhmann, Martin Ulrich Grimm, Florian Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title | Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title_full | Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title_fullStr | Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title_full_unstemmed | Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title_short | Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients |
title_sort | minimal effect of bevacizumab treatment on residual vestibular schwannomas after partial resection in young neurofibromatosis type 2 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966588/ https://www.ncbi.nlm.nih.gov/pubmed/31769423 http://dx.doi.org/10.3390/cancers11121862 |
work_keys_str_mv | AT gugelisabel minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT kluwelan minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT zipfeljulian minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT teuberchristian minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT tatagibamarcos minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT mautnervictorfelix minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT schuhmannmartinulrich minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients AT grimmflorian minimaleffectofbevacizumabtreatmentonresidualvestibularschwannomasafterpartialresectioninyoungneurofibromatosistype2patients |